BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

941 related articles for article (PubMed ID: 31182533)

  • 1.
    Kim DH; Jhun BW; Moon SM; Kim SY; Jeon K; Kwon OJ; Huh HJ; Lee NY; Shin SJ; Daley CL; Koh WJ
    Antimicrob Agents Chemother; 2019 Aug; 63(8):. PubMed ID: 31182533
    [TBL] [Abstract][Full Text] [Related]  

  • 2.
    Pang Y; Zheng H; Tan Y; Song Y; Zhao Y
    Antimicrob Agents Chemother; 2017 May; 61(5):. PubMed ID: 28242674
    [TBL] [Abstract][Full Text] [Related]  

  • 3.
    Yu X; Gao X; Li C; Luo J; Wen S; Zhang T; Ma Y; Dong L; Wang F; Huang H
    Antimicrob Agents Chemother; 2019 Aug; 63(8):. PubMed ID: 31138571
    [TBL] [Abstract][Full Text] [Related]  

  • 4.
    Luo J; Yu X; Jiang G; Fu Y; Huo F; Ma Y; Wang F; Shang Y; Liang Q; Xue Y; Huang H
    Antimicrob Agents Chemother; 2018 Jul; 62(7):. PubMed ID: 29760127
    [TBL] [Abstract][Full Text] [Related]  

  • 5.
    Brown-Elliott BA; Wallace RJ
    Antimicrob Agents Chemother; 2019 Feb; 63(2):. PubMed ID: 30509936
    [TBL] [Abstract][Full Text] [Related]  

  • 6.
    Kim DH; Kim SY; Koh WJ; Jhun BW
    Antimicrob Agents Chemother; 2021 Jun; 65(7):e0230620. PubMed ID: 33903101
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting bedaquiline mycobacterial efflux pump to potentially enhance therapy in
    Martin A; Bouyakoub Y; Soumillion K; Mantu EON; Colmant A; Rodriguez-Villalobos H
    Int J Mycobacteriol; 2020; 9(1):71-75. PubMed ID: 32474492
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Verapamil Improves the Activity of Bedaquiline against Mycobacterium abscessus In Vitro and in Macrophages.
    Viljoen A; Raynaud C; Johansen MD; Roquet-Banères F; Herrmann JL; Daher W; Kremer L
    Antimicrob Agents Chemother; 2019 Sep; 63(9):. PubMed ID: 31209005
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A bedaquiline/clofazimine combination regimen might add activity to the treatment of clinically relevant non-tuberculous mycobacteria.
    Ruth MM; Sangen JJN; Remmers K; Pennings LJ; Svensson E; Aarnoutse RE; Zweijpfenning SMH; Hoefsloot W; Kuipers S; Magis-Escurra C; Wertheim HFL; van Ingen J
    J Antimicrob Chemother; 2019 Apr; 74(4):935-943. PubMed ID: 30649327
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biofilm prevention concentration of clarithromycin against clinically relevant species of nontuberculous mycobacteria.
    Senhaji-Kacha A; Akir A; Broncano-Lavado A; Esteban J
    Rev Esp Quimioter; 2024 Jun; 37(3):266-269. PubMed ID: 38602224
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro activity of bedaquiline against slow-growing nontuberculous mycobacteria.
    Martin A; Godino IT; Aguilar-Ayala DA; Mathys V; Lounis N; Villalobos HR
    J Med Microbiol; 2019 Aug; 68(8):1137-1139. PubMed ID: 31210631
    [TBL] [Abstract][Full Text] [Related]  

  • 12.
    Sun Q; Liao X; Wang C; Jiang G; Yang J; Zhao J; Huang H; Wang G; Li H
    J Med Microbiol; 2022 Jun; 71(6):. PubMed ID: 35708979
    [No Abstract]   [Full Text] [Related]  

  • 13. Determination of MIC Distribution and Mechanisms of Decreased Susceptibility to Bedaquiline among Clinical Isolates of Mycobacterium abscessus.
    Li B; Ye M; Guo Q; Zhang Z; Yang S; Ma W; Yu F; Chu H
    Antimicrob Agents Chemother; 2018 Jul; 62(7):. PubMed ID: 29712658
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of the new GenoType NTM-DR kit for the molecular detection of antimicrobial resistance in non-tuberculous mycobacteria.
    Mougari F; Loiseau J; Veziris N; Bernard C; Bercot B; Sougakoff W; Jarlier V; Raskine L; Cambau E;
    J Antimicrob Chemother; 2017 Jun; 72(6):1669-1677. PubMed ID: 28333340
    [TBL] [Abstract][Full Text] [Related]  

  • 15.
    Brown-Elliott BA; Wallace RJ
    Antimicrob Agents Chemother; 2022 Sep; 66(9):e0068922. PubMed ID: 35943269
    [TBL] [Abstract][Full Text] [Related]  

  • 16.
    Schulthess B; Akdoğan Kittana FN; Hömke R; Sander P
    Antimicrob Agents Chemother; 2022 May; 66(5):e0234621. PubMed ID: 35420492
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro activity of bedaquiline against rapidly growing nontuberculous mycobacteria.
    Aguilar-Ayala DA; Cnockaert M; André E; Andries K; Gonzalez-Y-Merchand JA; Vandamme P; Palomino JC; Martin A
    J Med Microbiol; 2017 Aug; 66(8):1140-1143. PubMed ID: 28749330
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sudapyridine (WX-081) antibacterial activity against
    Zheng L; Wang H; Qi X; Zhang W; Wang B; Fu L; Chen X; Chen X; Lu Y
    mSphere; 2024 Feb; 9(2):e0051823. PubMed ID: 38240581
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Omadacycline drug susceptibility testing for non-tuberculous mycobacteria using oxyrase to overcome challenges with drug degradation.
    Boorgula GD; Gumbo T; Singh S; McShane PJ; Philley JV; Srivastava S
    Tuberculosis (Edinb); 2024 Jul; 147():102519. PubMed ID: 38754247
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recent advances in molecular diagnostics and understanding mechanisms of drug resistance in nontuberculous mycobacterial diseases.
    Huh HJ; Kim SY; Jhun BW; Shin SJ; Koh WJ
    Infect Genet Evol; 2019 Aug; 72():169-182. PubMed ID: 30315892
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 48.